Skip to content

Study · Case report or series · n = 1 · 2025

1 result

Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.

Maher CB, Guo B, Dunlop AA

Journal of surgical case reports25 Nov 2025Cited by 1 (Europe PMC)

PMID41306396 (opens in a new tab)PMCIDPMC12646242 (opens in a new tab)DOI10.1093/jscr/rjaf937 (opens in a new tab)PepBankPUB-41306396
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 43-year-old woman developed inflammatory optic neuritis and scleritis one month after starting semaglutide.

    In plain wordsOne woman developed inflammation of the optic nerve and the white of the eye one month after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableInflammatory optic neuritis and scleritis
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This study presents a unique case of inflammatory optic neuritis and scleritis in a 43-year-old female one month following commencement of semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.